Navigation Links
Green & Grow Inc. Secures $6M Series B Funding from Otter Capital
Date:8/27/2014

Austin, TX (PRWEB) August 27, 2014

Green & Grow Inc. (GGI) has raised an additional $6 million in Series B funding and secured Otter Capital as a significant new partner. Otter Capital’s expertise and investment capital will accelerate commercialization of GGI’s Agriplier™ technology, building on recent compelling field trial results across multiple crop types.

“Since our first meeting, we have been impressed with Otter Capital’s knowledge and commitment to the biological product space,” said Alan Sobba, President and CEO of GGI. “We look forward to John’s valuable input and guidance as we work together to complete the commercialization of our exciting technology.”

GGI’s range of Agriplier™ products is based on non-living, non-toxic, microbe derived by-products which contain specific metabolites and stimulants that significantly improve many crops. In the 2013 Independent Professional Seed Association (IPSA) trials, GGI products were the top performing yield enhancement seed treatment products across both corn and soybean, increasing yield over the current commercial seed treatment package. Independent researchers also observe visual improvements in early season plant vigor. Similar results have been demonstrated across a wide range of crops and geographies. The compatibility of Agriplier™ products with both existing chemical and living biological products is also a key differentiator, which will simplify the adoption of the technology.

“I am excited by the potential for selected biologically derived products to make a significant impact in the agriculture industry and the 2013 Green & Grow field trial results illustrate that its technology has already made the critical leap from the lab to achieving success in the field,” said John Pasquesi, Managing Member of Otter Capital and former Chairman of the Board of AgraQuest. “I look forward to working with the GGI team to optimize the delivery of their technology to market and to continue to build the business.”

GGI is currently mid-way through the process of working with industry partners, distributors and end-users to bring the Agriplier™ technology to market. Otter Capital’s investment and experience with this process will significantly assist GGI in selecting the most appropriate route to market and in completing this process.

GGI was represented by Sidley Austin LLP in the transaction, and Otter Capital was represented by Greene Radovsky Maloney Share & Hennigh LLP.

About Otter Capital

Otter Capital has a strong track record developing leading edge agriculture and food production companies. Otter was an early and consistent investor in AgraQuest, a leading biopesticide company. In 2012, Bayer CropScience acquired AgraQuest for $425 million plus earnouts. John Pasquesi previously served as Chairman of the Board of Directors of AgraQuest. More recently, Otter Capital invested alongside Khosla Ventures in a $15 million funding round for BioConsortia, Inc. - an agricultural biotechnology company.

Otter Capital was founded by John Pasquesi to make a variety of private equity investments. Prior to founding Otter Capital in 2001, he was a Managing Director and member of the Executive Committee of Hellman & Friedman LLC - a private equity investment firm. Prior to joining Hellman & Friedman in 1987, Pasquesi was associated with Golder, Thoma & Cressey - a Chicago-based private equity firm.

For more information on Otter Capital, please visit http://www.ottercapital.com.

About Green & Grow Inc.

Green & Grow Inc. (GGI) is dedicated to developing and commercializing biologically derived agricultural products.

Its first range of Agriplier™ products is based on non-living, non-toxic, microbe derived by-products which contain specific metabolites and stimulants that significantly improve many crops.

Agriplier™ products can be easily integrated into multiple seed treatment processes, as well as utilized as a soil amendment. As a non-living product, a key differentiator of Agriplier™ is that it can be easily integrated as an additive solution to both existing chemical and living biological products.

GGI has recently developed a line of OMRI listed products which utilize the Agriplier™ technology. These are being rolled out for ongoing trials with a small number of early adopters.

For more information about GGI and its technologies, please visit http://www.greenandgrow.com.

Agriplier™ is a registered trademark of Green & Grow Inc., a Delaware corporation.

###

Read the full story at http://www.prweb.com/releases/greenandgrow/agriplier/prweb12124330.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Infinity Group Invests US$4.2 M in Green BioTech Company BotanoCap
2. Green Dot Develops Compostable Synthetic Leather Made with its Terratek® Flex Bioplastic
3. A New Kind of Medical Thriller in Susy Gage's "Not Easy Being Green," Coming 2015 from Bitingduck Press
4. Cargill’s Dielectric Transformer Oil Made from Natural Esters Wins Presidential Green Chemistry Award
5. Topical BioMedics' Topricin Foot Therapy Cream for Diabetics Now Available in Walgreens' Diabetic Section
6. CareMetx, LLC Combines Operations with Walgreens-Owned Pharma Dynamics, Inc.
7. Green Dot Introduces New Terratek® WC Wood-Plastic Composite Pellets Optimized for Injection Molding and Sheet Extrusion
8. M&G Chemicals Launches Green Revolution in the Polyester Chain
9. Focus on Green Growth and Environmental Sustainability Drives the Global Market for Marine Biotechnology, According to New Report by Global Industry Analysts, Inc.
10. Robert Greenough’s New Book Examines Quantum Reality
11. Shocking News & Research: Boston Scientific, Yingli Green Energy Hold, QUALCOMM, PulteGroup, Regions Financial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" ... Liver Congress ("ILC") 2017 of the European Association for the ... on the positive effects of PBI-4050 on reduction of ... metabolic syndrome. ... Dr. Lyne Gagnon, Vice-President of R&D Pre-clinical of Prometic "This ...
(Date:4/20/2017)... ... April 20, 2017 , ... Open Therapeutics and the ... sharing and commercialization model. , The Center for Advancing Innovation helps institutions maximize ... effort is bringing the IP to the attention of the entrepreneurial community and ...
(Date:4/20/2017)... April 20, 2017 For today, Stock-Callers.com ... novel drug development and clinical research aimed at treating diseases ... (NASDAQ: BSTG), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Kite Pharma Inc. ... ). You can access our complimentary research reports on these ... ...
(Date:4/19/2017)... ... April 18, 2017 , ... Alisa Wright, founder and CEO ... from the Purdue College of Pharmacy in Lafayette, Indiana. , The Distinguished Alumni ... achievements in their careers and other scientific endeavors. , Wright began her career ...
Breaking Biology Technology:
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University (PolyU) ... ground breaking 3D fingerprint minutiae recovery and matching technology, pushing contactless ... use in identification, crime investigation, immigration control, security of access and ... ... A research team led by Dr Ajay Kumar ...
Breaking Biology News(10 mins):